Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H19ClN2O.ClH |
| Molecular Weight | 327.249 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CCOC(C1=CC=C(Cl)C=C1)C2=NC=CC=C2
InChI
InChIKey=QXDXEJNSYADHPX-UHFFFAOYSA-N
InChI=1S/C16H19ClN2O.ClH/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13;/h3-10,16H,11-12H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H19ClN2O |
| Molecular Weight | 290.788 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/carbinoxamine.html
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/carbinoxamine.html
Carbinoxamine is a histamine-H1 receptor blocking agent. It is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. Carbinoxamine is effective for the symptomatic treatment of seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis due to inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Most common adverse reactions are: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. Avoid concomitant use of alcohol and CNS depressants (hypnotics sedatives, tranquilizers, etc.) due to additive adverse effects.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 |
2.3 nM [Ki] | ||
Target ID: CHEMBL289 Sources: DOI: 10.14896/jssxmeeting.21.0.296.1 |
25.0 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
|||
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
|||
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
|||
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
|||
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
|||
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
|||
| Palliative | CARBINOXAMINE MALEATE Approved UseCarbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. Launch Date2003 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1363194 |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: PHENYLPROPANOLAMINE |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7488301 |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: PHENYLEPHRINE |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
13.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7488301 |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: PHENYLEPHRINE |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1363194 |
8 mg single, oral dose: 8 mg route of administration: Oral experiment type: SINGLE co-administered: PHENYLPROPANOLAMINE |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
30 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7488301 |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: PHENYLEPHRINE |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7488301 |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: PHENYLEPHRINE |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
31% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17339039 |
unknown, unknown |
CARBINOXAMINE MALEATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| 4-(4-Chloro-phen-yl)-4-hy-droxy-piperidinium maleate maleic acid solvate. | 2010-07-14 |
|
| LC for analysis of two sustained-release mixtures containing cough cold suppressant drugs. | 2010-07 |
|
| [1,2]-Anionic rearrangement of 2-benzyloxypyridine and related pyridyl ethers. | 2009-10-16 |
|
| Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening. | 2008-09-25 |
|
| Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. | 2007-04-20 |
|
| Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children. | 2007-03 |
|
| Mechanism of the condensation of homocysteine thiolactone with aldehydes. | 2006-10-25 |
|
| Spectrophotometric determination of carbinoxamine maleate in pharmaceutical formulations by ternary complex formation with Cu(II) and eosin. | 2006-06-01 |
|
| Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. | 2005-10 |
|
| Simultaneous determination of ingredients in a cold medicine by cyclodextrin-modified microemulsion electrokinetic chromatography. | 2005-03-09 |
|
| Quantitation of antihistamines in pharmaceutical preparations by liquid chromatography with a micellar mobile phase of sodium dodecyl sulfate and pentanol. | 2002-01-05 |
|
| Cold-syrup induced movement disorder. | 2001-06 |
|
| Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001-04 |
|
| [Serous otitis media. Comparative study of carbinoxamine- pseudoephedrine vs astemizole-pseudoephedrine]. | 1997-05-01 |
|
| The need for rational therapeutics in the use of cough and cold medicine in infants. | 1992-04 |
|
| [Antimycobacterial antihistaminics]. | 1989-08 |
|
| Clistin maleate; a clinical appraisal of a new antihistaminic. | 1954-11 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:41:20 GMT 2025
by
admin
on
Mon Mar 31 21:41:20 GMT 2025
|
| Record UNII |
VLF7M9C64J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6033-93-8
Created by
admin on Mon Mar 31 21:41:20 GMT 2025 , Edited by admin on Mon Mar 31 21:41:20 GMT 2025
|
PRIMARY | |||
|
VLF7M9C64J
Created by
admin on Mon Mar 31 21:41:20 GMT 2025 , Edited by admin on Mon Mar 31 21:41:20 GMT 2025
|
PRIMARY | |||
|
18913831
Created by
admin on Mon Mar 31 21:41:20 GMT 2025 , Edited by admin on Mon Mar 31 21:41:20 GMT 2025
|
PRIMARY | |||
|
DTXSID20975741
Created by
admin on Mon Mar 31 21:41:20 GMT 2025 , Edited by admin on Mon Mar 31 21:41:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |